Richa Gujarati, Pooja Chatterjee Join HeartBeam’s Senior Management Team

HeartBeam Inc. has appointed Richa Gujarati as senior vice president, Product; and Pooja Chatterjee as vice president, Clinical.

“We welcome Richa and Pooja to HeartBeam’s leadership team and look forward to leveraging their extensive experience to help bring our ambulatory VECG products to market,” HeartBeam Founder/CEO Branislav Vajdic, Ph.D., said. “Richa’s deep expertise in go-to-market strategies for health sensing technologies will be instrumental as we ready the HeartBeam AIMIGo VECG device for limited market release during the second half of 2024. Pooja will play a pivotal role leading the validation of our technologies, including FDA 510(k) clearance for the HeartBeam AIMIGo VECG device and post-market regulatory required studies. Together they will add to our growing team of medical and technology experts as we progress toward our initial clearances and the commercial availability of our technology.”
 
Gujarati has more than 13 years experience collecting market-level insights and translating them into business needs, driving overall product portfolio and go-to-market strategy. Gujarati most recently was vice president of Product and Go-To-Market Strategy at NextSense. Before that, she was head of Health Products, Apple Watch, at Apple, building and launching applications in the wearable sensor space, including exploring new revenue models through payer and pharmaceutical partnerships. She was also senior manager, Product Management and Marketing at iRhythm Technologies, focused on building and selling the Zio line of digital cardiac monitoring products and associated patient apps and electronic health records integration services.

Gujarati earned a bachelor of science degree in biomedical and electrical engineering from the University Of Rhode Island; a master of science degree in biomedical device design and innovation from Johns Hopkins University; and an MBA in product innovation and design from Haas School of Business, UC Berkeley.
 
Chatterjee has more than 15 years of extensive clinical leadership experience in the medical device industry. Her expertise spans a wide range of clinical responsibilities, including field engineering, clinical portfolio strategy and study execution resulting in multiple U.S. Food and Drug Administration (FDA) approvals. She has hands-on experience with a wide range of medical technologies including heart failure, electrophysiology, cardiac rhythm management, diagnostics, and sleep therapy. Previously Chatterjee held several positions at Abbott Medical Devices, most recently as global clinical project director, where she defined and executed clinical goals leading to product approvals, indication expansion and publications in key journals.

Chatterjee earned a bachelor’s degree in engineering from the University of Pune; a master of science degree in biomedical engineering from the New Jersey Institute of Technology; and an MBA in marketing and strategy from New York University Stern School of Business.
 
Gujarati has direct responsibility for product roadmap and go-to-market strategy and execution at HeartBeam while Chatterjee is responsible for strategic and tactical leadership of the clinical pipeline, with the objective of securing FDA clearances to support commercialization.
 
HeartBeam Inc. is a cardiac technology company that has developed the first and only 3D-vector ECG platform intended for patient use at home. By applying a suite of proprietary algorithms to simplify vector electrocardiography (VECG), the HeartBeam platform enables patients and their clinicians to assess their cardiac symptoms quickly and easily. HeartBeam AIMIGo is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote evaluation of cardiac symptoms. By collecting 3D signals of the heart’s electrical activity, HeartBeam AIMIGo has the potential to provide unparalleled data for the development of AI algorithms. HeartBeam AIMIGo has not yet been cleared by the FDA for marketing in the United States or other geographies.